252 related articles for article (PubMed ID: 32885271)
1. Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario.
Lerner-Ellis J; Mighton C; Lazaro C; Watkins N; Di Gioacchino V; Wong A; Chang MC; Charames GS
J Cancer Res Clin Oncol; 2021 Mar; 147(3):871-879. PubMed ID: 32885271
[TBL] [Abstract][Full Text] [Related]
2. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
3. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
[TBL] [Abstract][Full Text] [Related]
4. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
5. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
6. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
[TBL] [Abstract][Full Text] [Related]
7. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract][Full Text] [Related]
8. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
9. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
[TBL] [Abstract][Full Text] [Related]
10. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.
Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW
J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792
[TBL] [Abstract][Full Text] [Related]
12. Retesting of women who are negative for a
Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study.
Adam F; Fluri M; Scherz A; Rabaglio M
BMC Med Genomics; 2023 Jan; 16(1):7. PubMed ID: 36647026
[TBL] [Abstract][Full Text] [Related]
15. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
16. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
17. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
18. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
Akcay IM; Celik E; Agaoglu NB; Alkurt G; Kizilboga Akgun T; Yildiz J; Enc F; Kir G; Canbek S; Kilic A; Zemheri E; Ezberci F; Ozcelik M; Dinler Doganay G; Doganay L
Int J Cancer; 2021 Jan; 148(2):285-295. PubMed ID: 32658311
[TBL] [Abstract][Full Text] [Related]
19. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
20. The results of multigene panel sequencing in Slovak HBOC families.
Konecny M; Kosova K; Tilandyova P; Wachsmannova L; Baldovic M; Krajcovic J; Patlevicova A; Markus J; Ciernikova S
Neoplasma; 2021 May; 68(3):652-664. PubMed ID: 33724863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
